The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
Summit and Nuvalent have scored prized plenary spots.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Inclacumab fails, and osivelotor is on hold.
Shortly after ponsegromab, visugromab is to start phase 2/3.
J&J, Astra, Pfizer and others move yet more ADCs into human studies.